Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.08. | Appili Therapeutics GAAP EPS of -$0.01 | 1 | Seeking Alpha | ||
14.08. | Appili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026 | 95 | GlobeNewswire (Europe) | Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium, strengthening... ► Artikel lesen | |
06.08. | Appili Therapeutics Inc: Appili releases tularemia vaccine results | 1 | Stockwatch | ||
06.08. | Appili Therapeutics Inc.: Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine | 1 | GlobeNewswire (USA) | ||
26.06. | Appili Therapeutics Inc.: Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results | 911 | GlobeNewswire (Europe) | LIKMEZ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia... ► Artikel lesen | |
30.05. | Stocks in Play: Appili Therapeutics Inc. | 1 | Baystreet.ca | ||
30.05. | Appili Therapeutics Inc.: Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. | 281 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:... ► Artikel lesen | |
APPILI THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
20.05. | Appili Therapeutics Inc: Appili to receive termination fee from Aditxt | 1 | Stockwatch | ||
19.05. | Aditxt to terminate arrangement agreement with Appili Therapeutics | 1 | Seeking Alpha | ||
19.05. | Appili Therapeutics Inc.: Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. | 253 | GlobeNewswire (Europe) | NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink:... ► Artikel lesen | |
01.05. | Appili Therapeutics Inc.: Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia | 1 | GlobeNewswire (USA) | ||
28.04. | Appili Therapeutics Inc: Appili Therapeutics granted patents in U.S., Mexico | 1 | Stockwatch | ||
28.04. | Stocks in Play: Appili Therapeutics Inc. | - | Baystreet.ca | ||
28.04. | Appili Therapeutics Inc.: Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ | 164 | GlobeNewswire (Europe) | New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S.... ► Artikel lesen | |
02.04. | Appili Therapeutics Inc: Appili president to join Aditxt's April 4 update | 2 | Stockwatch | ||
02.04. | Appili Therapeutics Inc.: Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025 | 2 | GlobeNewswire (USA) | ||
18.03. | Appili Therapeutics Inc: Appili Therapeutics submits U.S. funding applications | 1 | Stockwatch | ||
18.03. | Stocks in Play: Appili Therapeutics Inc. | 1 | Baystreet.ca | ||
18.03. | Appili Therapeutics Inc.: Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update | 205 | GlobeNewswire (Europe) | Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOutside date for going-private transaction... ► Artikel lesen | |
14.02. | Appili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025 | 720 | GlobeNewswire (Europe) | Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ABBVIE | 179,60 | -0,22 % | AbbVie's RINVOQ Secures Health Canada's Approval For Giant Cell Arteritis Treatment | WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV), Wednesday announced Health Canada has issued a Notice of Compliance for RINVOQ for the treatment of adults with giant cell arteritis, both used in... ► Artikel lesen | |
INNOCAN PHARMA | 0,131 | +3,56 % | "Poster"-News: Innocan Pharma - Durchbruch auf der PAINWEEK! | ||
TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | CSE Bulletin: Suspensions - Blender Bites Limited, TAAT Global Alternatives Inc. | Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2025) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as... ► Artikel lesen | |
DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Provides Update Regarding Proposed RTO Transaction | / Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. ("Digicann" or... ► Artikel lesen | |
TONIX PHARMACEUTICALS | 25,400 | 0,00 % | Tonmya-Zulassung in den USA: "Dirty Drug" Cyclobenzaprin bei Fibromyalgie | ||
AEQUUS PHARMACEUTICALS | 0,005 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 13.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.05.2025ISIN NameUS2310828015 CUMULUS... ► Artikel lesen | |
SHANGHAI PHARMACEUTICALS | 1,410 | +3,68 % | SH PHARMA (02607): ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2025 | ||
CIPHER PHARMACEUTICALS | 9,550 | +1,06 % | Cipher Pharmaceuticals Announces the Passing of Director Mr. Harold Wolkin | ||
BAYER | 28,060 | +0,48 % | Massive UNTERBEWERTUNG?! Bayer, SFC Energy, Veganz Group Aktie | Massive Unterbewertung bei der Veganz-Aktie? Die Transformation vom Anbieter veganer Lebensmittel zum Food-Tech-Unternehmen nimmt immer mehr Form. Die erste Lieferung der in einem revolutionären Verfahren... ► Artikel lesen | |
MERCK KGAA | 108,30 | +0,70 % | BERNSTEIN RESEARCH stuft MERCK KGAA auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Merck KGaA von 147 auf 138 Euro gesenkt, aber die Einstufung auf "Market-Perform" belassen. Florent Cespedes... ► Artikel lesen | |
NOVO NORDISK | 48,180 | +0,16 % | Novo Nordisk: Volltreffer! Sie waren rechtzeitig informiert! | ||
HARROW | 39,000 | +0,03 % | Harrow, Inc. (HROW): A Bull Case Theory | ||
CANOPY GROWTH | 1,520 | -0,39 % | Aktien-Trading 4 Dummies - 3 Aktien. 2 Experten. 0 Langeweile (Apple, Canopy Growth & Alcon) | ||
PFIZER | 21,150 | -0,02 % | Pfizer Inc.: Pfizer and BioNTech's COMIRNATY Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 | The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted... ► Artikel lesen | |
TILRAY BRANDS | 1,181 | -0,51 % | Kursziel 2 US-Dollar: Trumps Cannabis-Kurswechsel: Tilray-Aktie im Kursrausch | © Foto: Bebeto Matthews - APDie Cannabis-Branche in den USA steht vor einem möglichen Richtungswechsel - und Tilray könnte der große Profiteur sein. Das Analysehaus Jefferies hebt sein Kursziel an,... ► Artikel lesen |